🧵Thread on frontline caplacizumab and plasma exchange in TTP🚨 With advancing care for immune thrombotic thrombocytopenic purpura (iTTP), let’s discuss frontline caplacizumab (capla) and the future for therapeutic plasma exchange (TPE) ⤵️ #hemetwitter #TTP #caplacizumab 1/22

CON URGENCIA SE NECESITA MEDICAMENTO ✨Valentine ✨ #venezuela #ayuda #caplacizumab

🚨Article Alert🚨 Frontline use of #rituximab may prevent ADAMTS13 inhibitor boosting during #caplacizumab treatment in patients with #iTTP: post hoc analysis of a phase 2/3 study in Japan 💉🩸 #OpenAccess #Hematology #ThrombosisResearch Read the Article: doi.org/10.1186/s12959…

#Caplacizumab in #paediatric immune thrombotic thrombocytopenic purpura (iTTP): the UK TTP Registry experience ashpublications.org/bloodadvances/…

#TTP #Caplacizumab

#ITTP #caplacizumab

#ISTH2024 #caplacizumab

Without the adamts13 result #caplacizumab cannot be utilised for suspected #TTP, which if it is TTP puts the affected person at higher risk of complications. Expertise with the drug is recommended. #ISTH2024 Our local outcomes have significantly improved since introduction

Ahir el Dr. Xavier Solanich ens parlava de la #PTTa: la perspectiva històrica, ara que fa 100anys de la seva descripció, les novetats terapèutiques com el #caplacizumab, que n’han permès millorar el pronòstic, i perspectives de futur (#ADAMTS13 recombinant, etc.) #hbellvitge 👇

Dr. Yada et al KU Pathology & Laboratory Medicine report the novel role of recombinant #ADAMTS13 and #caplacizumab in preventing #neutrophil #extracellular trap (NET) formation and inhibiting #inflammation and #thrombosis in immune TTP. doi.org/10.1182/blooda….

#caplacizumab #ASH2023 #ITTP #TTP

Largest real-world data on #caplacizumab in #TTP, impressive study & data. Survival advantage at 3 months, with less exacerbations/refractoriness. 2.2% major bleeding rate. Should have been an oral. #ASH23

#ITTP #Caplacizumab #Hematology #ASH

#Caplacizumab #ITTP Great work.

Further RWE supports the use of #caplacizumab in #TTP, including in those mildly affected without plasma exchange. 2 bleed events were both in individuals with predisposing comorbidities & reinforces the need for global view of the person's condition rpthjournal.org/article/S2475-…

Dr. Andrea Artoni discusses evidence from clinical trials on #caplacizumab in #ttp at the #ECTH2023 Congress Policlinico di Milano